Clinical Trial: NCT06004336
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | M.D. Anderson Cancer Center |
| Information Provided By: | M.D. Anderson Cancer Center |
| Last Update Posted: | 2026-07-16 |
Study Overview
Brief Summary
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Official Title
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Conditions
Oligometastatic Renal Cell Carcinoma
Intervention / Treatment
- Drug: Pembrolizumab
- Radiation: Radiation therapy
Other Study ID Numbers
- 2023-0006
- NCI-2023-06314
Start Date (Actual)
2023-10-31
Primary Completion Date (Estimated)
2029-01-01
Study Completion Date (Estimated)
2029-01-01
Enrollment (Estimated)
144
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | M.D. Anderson Cancer Center |
| Information Provided By: | M.D. Anderson Cancer Center |
| Last Update Posted: | 2026-07-16 |
Study Overview
Brief Summary
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Official Title
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Conditions
Oligometastatic Renal Cell Carcinoma
Intervention / Treatment
- Drug: Pembrolizumab
- Radiation: Radiation therapy
Other Study ID Numbers
- 2023-0006
- NCI-2023-06314
Start Date (Actual)
2023-10-31
Primary Completion Date (Estimated)
2029-01-01
Study Completion Date (Estimated)
2029-01-01
Enrollment (Estimated)
144
Study Type
Interventional
Phase
Phase 2